Notably, recent investigations have reported a more significant accumulation of PD1+CD28+ T cells at tumor sites in NSCLC patients [44], likely mediated by the impact of CD28 on T-cell tissue localization following antigen priming. This evidence concerns the gene CD28 and neoplasm.